Mettler-Toledo raises annual profit forecast on strong demand for lab instruments
Mettler-Toledo International raised its annual profit forecast due to strong demand for laboratory instruments, particularly in drug development. The company now expects 2025 adjusted profit between $42.10 and $42.60 per share, up from $41.25 to $42. Analysts had anticipated $41.60. Despite challenges from shipping delays and tariffs, Mettler-Toledo reported second-quarter sales of $983.22 million, exceeding estimates, and an adjusted profit of $10.09 per share, surpassing expectations of $9.61.
July 31 (Reuters) - Mettler-Toledo International (MTD.N) raised its profit forecast for the year on Thursday, after posting better-than-expected second-quarter results, driven by strong demand for its laboratory instruments used in drug development.
The Columbus, Ohio-based company forecast 2025 adjusted profit in the range of $42.10 to $42.60 per share, compared with its previous projection of $41.25 to $42. Analysts were expecting a profit of $41.60 per share, according to data compiled by LSEG.
The company said its full-year forecast accounts for a 4% impact from earlier shipping delays and an additional 4% drag from higher tariffs, although it expects most of the tariff costs to be offset by mitigation efforts this year.
Mettler-Toledo also said that it was now expecting third-quarter adjusted profit in the range of $10.55 to $10.75 per share, compared with estimates of $10.47 apiece.
The firm’s second-quarter sales came in at $983.22 million, surpassing analysts’ estimate of $957.9 million.
On an adjusted basis, Mettler-Toledo earned a profit of $10.09 per share for the quarter ending June 30, topping analysts’ estimates of $9.61 each.
The company designs and produces precision instruments, including laboratory balances, industrial scales, analytical instruments, and product inspection systems, which are used across sectors like pharmaceuticals, food processing, and chemicals.
